Efficacy and safety of adjuvant capecitabine and pembrolizumab in early-stage triple-negative breast cancer after standard neo-/adjuvant chemotherapy: A meta-analysis of phase III studies
Journal of Oncology Pharmacy Practice
Published online on January 13, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
BackgroundTriple-negative breast cancer (TNBC) is a subtype of breast cancer with high recurrence rates and poor prognosis. Capecitabine and pembrolizumab are emerging therapies aimed at improving survival outcomes in early-stage TNBC. This meta-analysis ...
BackgroundTriple-negative breast cancer (TNBC) is a subtype of breast cancer with high recurrence rates and poor prognosis. Capecitabine and pembrolizumab are emerging therapies aimed at improving survival outcomes in early-stage TNBC. This meta-analysis ...